Table 2 Analysis of potential risk factors for excessively prolonged meropenem therapy

age

<50

1

0.44

-

-

-

50-70

0.72

0.25–2.04

≥70

0.49

0.16–1.53

sex

male

1

0.76

-

-

-

female

1.13

0.51–2.49

malignancy

No

1

0.002

1

0.84

Yes

3.5

1.57–7.82

1.14

0.32–4.06

SAPS at admission

<40

1

0.33

-

-

-

≥40

1.45

0.68–3.11

patient group

medical

1

<0.001

1

0.31

neurological

2.41

0.63–9.30

2.79

0.65 – 11.92

surgical

8.36

2.67–26.17

2.46

0.50 – 11.98

colonization with carbapenem-susceptible, MDR bacteria

no

1

0.01

1

0.004

yes

4.12

1.38–12.35

7.52

1.88–30.14

type of infection

pneumonia

1

<0.001

1

<0.001

peritonitis

21.60

5.05–92.35

16.96

2.95 – 97.49

mediastinitis

10.12

1.96–52.41

6.27

0.81 – 48.76

unclear focus

0.94

0.27–3.24

0.77

0.21 – 2.84